1. Brennan F. H., Lee J. D., Ruitenberg M. J., Woodruff T. M. Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions // Semin Immunol. 2016. 28(3). P. 292–308.
2. Alawieh A., Tomlinson S. Injury site-specifi c targeting of complement inhibitors for treating stroke // Immunol. Rev. 2016. Vol. 274 (1). P. 270–280.
3. Alawieh A., Elvington A., Zhu H., Yu J., Kindy M. S., Atkinson C., Tomlinson S., Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement //J Neuroinfl ammation. 2015. Vol.12. P. 247–259.
4. Mastellos D. C., Reis E. S., Yancopoulou D., Hajishengallis G., Ricklin D., Lambris J. D. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage // Immunobiology. 2016. Oct. Vol.221(10).P.1046–57.